Anti-Mouse VEGF Antibody (G6-31)

Name: Anti-Mouse VEGF Antibody (G6-31)
Brand: MedChemExpress
SKU: HY-P992086

Cat. No.: HY-P992086: Ficha de datos
FAQs
Technical Support

Anti-Mouse VEGF Antibody (G6-31) is a anti-mouse VEGF antibody. Anti-Mouse VEGF Antibody (G6-31) blocks VEGF-A-mediated angiogenesis and shows antitumor activity. Anti-Mouse VEGF Antibody (G6-31) can be used for the research of cancer, such as multiple endocrine neoplasia type 1.

Para uso exclusivo en investigación. No vendemos a pacientes.

Anti-Mouse VEGF Antibody (G6-31) Estructura química

Tamaño		Stock
MOQ		Minimum order quantity
1 mg		Obtener un presupuesto
5 mg		Obtener un presupuesto
10 mg		Obtener un presupuesto
Other size		Obtener un presupuesto

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Recomendaciones destacadas

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas VEGFR:

Ver todas las isoformas

VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

Isotype

Mouse IgG2a kappa

Recommend Isotype Controls

Mouse IgG2a kappa, Isotype Control

Species Reactivity

Mouse

In Vivo

Anti-Mouse VEGF Antibody (G6-31) (5 mg/kg; i.p.; once weekly; 67 days) produces a 72% reduction in mean pituitary adenoma volume, increases tumor doubling-free survival, lowers serum prolactin levels, and reduces vascular density in Men1^+/- mice with spontaneous pituitary adenomas^[1].
Anti-Mouse VEGF Antibody (G6-31) (5 mg/kg; i.p.; once weekly; 35 days) produces a 73% reduction in mean subcutaneous pituitary adenoma transplants volume and lowers serum prolactin levels in BALB/c nude mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Men1^+/- mice (female, mixed 129-FVB background, 13.5 to 14.5 months of age, spontaneous pituitary adenomas)^[1]
Dosage:	5 mg/kg
Administration:	i.p.; once weekly; 67 days
Result:	Reduced mean pituitary adenoma volume by 72% at day 67. Increased tumor doubling-free survival, with 2 of 8 mice showing no tumor doubling by day 67. Reduced mean serum prolactin level to 5,163.7 ± 1,608.9 ng/mL at study end point, a significant decrease compared to control. Reduced pituitary tumor vascular density to 46% of control levels. Significantly elevated mean relative expression of VEGF-A in treated tumors. Significantly lowered mean expression levels of VEGFR-1, VEGFR-2, CD31, and Tie-2 compared to control.

Animal Model:	BALB/c nude (female, 6 to 8 weeks old at grafting, treated 4 months post-grafting, subcutaneous grafted Men1+/- pituitary adenomas)^[1]
Dosage:	5 mg/kg
Administration:	i.p.; once weekly; 35 days
Result:	Reduced mean subcutaneous tumor volume by 73% at day 35 (P < 0.0001); mean tumor volume remained stable at 556 ± 89 mm³ compared to a quadrupling of volume in controls. Significantly reduced serum prolactin levels at day 35 compared to control, while levels were comparable between groups at treatment onset.

Target

VEGF

Application

ELISA, FACS, Functional assay, Research in vivo

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

SMILES

[Anti-Mouse VEGF Antibody (G6-31)]

Formulation

Please refer to the lot-specific COA for specific buffer information.

Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureza y Documentación

Inhibitory Antibodies User Guide (603 KB)

Referencias

[1]. Korsisaari N, et al. Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1. Clin Cancer Res. 2008;14(1):249-258. [Content Brief]